Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial

被引：0
|
作者：
Lutz van Heek
Colin Stuka
Helen Kaul
Horst Müller
Jasmin Mettler
Felicitas Hitz
Christian Baues
Michael Fuchs
Peter Borchmann
Andreas Engert
Markus Dietlein
Conrad-Amadeus Voltin
Carsten Kobe
机构：
[1] University of Cologne,Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne
[2] University of Cologne,First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne
[3] Swiss Group for Clinical Cancer Research,Department of Medical Oncology and Haematology
[4] Kantonsspital St.Gallen,Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and UniversityHospital Cologne
[5] University of Cologne,undefined
来源：
BMC Cancer | / 22卷
关键词：
Hodgkin lymphoma; Metabolic tumor volume; FDG PET; Response prediction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group
    Fuchs, Michael
    Jacob, Anne Sophie
    Kaul, Helen
    Kobe, Carsten
    Pabst, Thomas
    Greil, Richard
    Eichenauer, Dennis A.
    Topp, Max
    Just, Marianne
    Hertenstein, Bernd
    Schaub, Valdete
    Vogelhuber, Martin
    Zijlstra, Josee M.
    Pluetschow, Annette
    Baues, Christian
    Rosenwald, Andreas
    Dietlein, Markus
    Borchmann, Peter
    Engert, Andreas
    BLOOD, 2021, 138
  • [12] Positron Emission Tomography- (PET) guided Treatment in early-Stage Hodgkin Lymphoma with favorable Risk Factors: Final Results of the international randomized Phase III HD16 Trial conducted by the German Hodgkin Study Group
    Nieder, Carsten
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (04) : 414 - 415
  • [13] Pet positivity after 2 cycles of abvd is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study
    Fuchs, M.
    Goergen, H.
    Kobe, C.
    Kuhnert, G.
    Hitz, F.
    Greil, R.
    Sasse, S.
    Topp, M. S.
    Schaefer, E.
    Hertenstein, B.
    Soekler, M.
    Vogelhuber, M.
    Zijlstra, J. M.
    Keller, U. B.
    Krause, S. W.
    Wilhelm, M.
    Maschmeyer, G.
    Thiemer, J.
    Duehrsen, U.
    Meissner, J.
    Viardot, A.
    Eich, H.
    Baues, C.
    Diehl, V.
    Rosenwald, A.
    von Tresckow, B.
    Dietlein, M.
    Borchmann, P.
    Engert, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 297 - 297
  • [14] Radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17) A multicentre phase III trial
    Suess, Christoph
    Koelbl, Oliver
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (10) : 946 - 949
  • [15] Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial
    Voltin, Conrad-Amadeus
    Mettler, Jasmin
    Mueller, Horst
    Fuchs, Michael
    Baues, Christian
    Dietlein, Markus
    Engert, Andreas
    Borchmann, Peter
    Kobe, Carsten
    Brockelmann, Paul J.
    BLOOD, 2019, 134
  • [16] Treatment of Early-Stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Subgroup Analysis of the Randomized German Hodgkin Study Group HD16 Study
    Eichenauer, Dennis A.
    Buehnen, Ina
    Fuchs, Michael
    Kaul, Helen
    Kobe, Carsten
    Hartmann, Sylvia
    Baues, Christian
    Von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    BLOOD, 2021, 138
  • [17] Positronenemissionstomographie(PET)-geleitete Behandlung des Hodgkin-Lymphoms im frühen Stadium mit günstigen Risikofaktoren: Endresultate der internationalen randomisierten Phase-III-HD16-Studie der Deutschen Hodgkin-StudiengruppePositron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international randomized phase III HD16 trial conducted by the German Hodgkin Study Group
    Carsten Nieder
    Strahlentherapie und Onkologie, 2020, 196 (4) : 414 - 415
  • [18] IMPACT OF BLEOMYCIN AND DACARBAZINE WITHIN THE ABVD REGIMEN IN THE TREATMENT OF EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE GHSG HD13 TRIAL
    Behringer, K.
    Goergen, H.
    Borchmann, P.
    Diehl, V.
    Fuchs, M.
    Lohri, A.
    Hitz, F.
    Zijlstra, J. M.
    Greil, R.
    Markova, J.
    Topp, M. S.
    Soekler, M.
    Mathas, S.
    Meissner, J.
    von Tresckow, B.
    Boell, B.
    Engert, A.
    HAEMATOLOGICA, 2014, 99 : 497 - 497
  • [19] LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD7 AND HD10 TRIAL
    Sasse, S.
    Broeckelmann, P. J.
    Goergen, H.
    Pluetschow, A.
    Mueller, H.
    Kreissl, S.
    Buerkle, C.
    Borchmann, S.
    Fuchs, M.
    Borchmann, P.
    Engert, A.
    HAEMATOLOGICA, 2016, 101 : 12 - 12
  • [20] Metabolic tumor volume after two cycles of chemotherapy in patients treated for advanced-stage Hodgkin Lymphoma: analysis of the German Hodgkin Study Group phase III HD18 and HD21 trials
    Kobe, C.
    Kaul, H.
    Schneider, G.
    Fuchs, M.
    Eich, H.
    Rosenbrock, J.
    Baues, C.
    Roth, K.
    Drzezga, A.
    van Heek, L.
    Dietlein, M.
    Borchmann, P.
    Ferdinandus, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S234 - S234
12345